---
title: "SYNERGY: Agomelatine and Opicapone have obtained drug registration certificates in South Korea"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249549659.md"
description: "According to the Zhitong Finance APP, SYNERGY announced that the company recently received the drug registration certificates for Agomelatine and Opicapone issued by the Ministry of Food and Drug Safety (MFDS) of South Korea"
datetime: "2025-07-22T09:45:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249549659.md)
  - [en](https://longbridge.com/en/news/249549659.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249549659.md)
---

# SYNERGY: Agomelatine and Opicapone have obtained drug registration certificates in South Korea

According to the Zhitong Finance APP, SYNERGY (300636.SZ) announced that the company recently received the drug registration certificates for Agomelatine and Opicapone issued by the Ministry of Food and Drug Safety (MFDS) of South Korea

### Related Stocks

- [300636.CN](https://longbridge.com/en/quote/300636.CN.md)

## Related News & Research

- [Chemtrade Logistics Holds Guidance Amid Commodity Swings](https://longbridge.com/en/news/286831060.md)
- [PRECIOUS-Treasury yields, dollar weigh on gold amid inflation concerns](https://longbridge.com/en/news/286929968.md)
- [Alibaba unveils new Qwen model, custom chips in bid to become China’s AI factory](https://longbridge.com/en/news/287044112.md)
- [HSA warns public against consuming herbal remedy containing potent steroid](https://longbridge.com/en/news/287022845.md)
- [JPMorgan lowers 2026 gold forecast, still sees rally towards $6,000 on renewed demand](https://longbridge.com/en/news/286715908.md)